Caplin Point Laboratories Ltd.

₹2,754.9

-40.5 (-1.4%)

CAPLIPOINT Share Price

Pharmaceuticals & Biotechnology

As on September 11, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 20,918 Cr

P/E Ratio32.65

Dividend Yield0.15 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,771.5	Bearish
10-DMA	2,746.24	Bullish
20-DMA	2,635.89	Bullish
50-DMA	2,599.27	Bullish
100-DMA	2,352.1	Bullish
200-DMA	2,063.71	Bullish

Historical Performance

1 Year

23.1%

3 Years

165.6%

5 Years

195.2%

10 Years

949.9%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	21,872	19,375	16,941	14,667	12,694
Total Expenditure	14,263	12,905	11,427	10,262	8,749
Other Income	1,155	964	669	565	389
Operating Profit	8,764	7,434	6,184	4,970	4,334
Interest	9	6	8	8	7
Depreciation	728	660	534	450	469
Profit Before Tax	8,028	6,768	5,644	4,514	3,858
Consolidated Net Profit	6,412	5,363	4,571	3,763	2,998
Adjusted EPS	84	71	60	50	40

Compounded Sales Growth

10 Years:55.7

5 Years:15.6

3 Years:8.3

TTM:2.5

Compounded Profit Growth

10 Years:69.5

5 Years:21.5

3 Years:11.3

TTM:3.6

Stock Price CAGR

10 Years:26.7

5 Years:23.6

3 Years:40.1

TTM:22.7

Return on Equity

10 Years:12.7

5 Years:39.6

3 Years:60.2

last year:84.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	898	898	898	898	897
Total Reserves	34,783	27,411	22,117	17,753	13,787
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	208	132	79	21	126
Other Current Liabilities	693	643	903	999	487
Short Term Borrowings	6	6	3	34	5
Total Liabilities	40,375	32,056	26,856	21,774	17,301
Capital Work in Progress	2,086	1,392	1,166	2,205	154
Long Term Loans & Advances	1,511	886	783	515	899
Currents Investments	3,857	3,113	2,380	2,102	520
Short Term Loans and Advances	2,263	1,855	1,460	1,434	2,249
Total Current Assets	25,857	21,339	18,929	15,522	12,978
Total Assets	40,375	32,056	26,856	21,774	17,301
Adjusted Book Value	460	363	293	236	184

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 32.65, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 40.1%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹8764 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹21872 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1211850.6

No. of Shares: 440 (Approx)

Performance:21.2%

211850.6

NIFTY Performance: -6.8%

1 day Top Gainers